Constitution of a Clinical, Neurophysiological and Biological Cohort for Chronic Sleep Disorders Responsible of Hypersomnolence

Status: Recruiting
Location: See location...
Intervention Type: Genetic, Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Chronic sleep disorders result from multiple pathophysiological mechanisms and are often associated with severe hypersomnolence, responsible for major disability. Hypersomnolence may be secondary to sleep disturbances at night by sleep fragmentation, both overall in restless leg syndrome (RLS) or specific to slow or paradoxical sleep in parasomnias (sleepwalking, sleep behavior disorder). paradoxical). Attention-Deficit / Hyperactivity Disorder (ADHD) is another cause of secondary hypersomnolence, unsolved pathophysiology, leading to a major disturbance of alertness. More rarely, hypersomnolence may be primary (central hypersomnia), representing then the most severe form existing in humans. The best-known central hypersomnia is narcolepsy type 1 (NT1), affecting 0.02% of the population. It is thanks to the existence of well-characterized clinical, biological and neuropathological patients that its pathophysiology is better understood. It is due to a selective loss of hypothalamic neurons secreting orexin / hypocretin, in connection with a probable autoimmune process, in genetically predisposed subjects. Narcolepsy type 2 (NT2), idiopathic hypersomnia (HI) and Kleine-Levin syndrome (SKL), are rarer forms of central hypersomnia, the pathophysiology of which is still unknown, due to the small number of patients studied.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 6
Healthy Volunteers: f
View:

• Have a complaint of chronic hypersomnolence on questioning, identified by a sleep specialist and requiring objective explorations in the Centre de Hypersomnias Rares, with or without a diagnosis of chronic sleep disorder according to the International Classification scale in force at the time of diagnosis

• can be treated or not for chronic sleep disorder.

• speak and understand french

• should have a social security system

• should not have infectious or inflammatory pathology

Locations
Other Locations
France
UH Montpellier
RECRUITING
Montpellier
Contact Information
Primary
Pôle Recherche et Innovation
depotac@chu-montpellier.fr
0033467330913
Time Frame
Start Date: 2020-06-16
Estimated Completion Date: 2033-06-16
Participants
Target number of participants: 5000
Treatments
Other: chronic sleep disorders
Subjects with chronic sleep disorders responsible of hypersomnolence measured by a scale of severity of sleep disorder, and blood parameters (blood sample)
Sponsors
Leads: University Hospital, Montpellier
Collaborators: INSERM U1061 Montpellier

This content was sourced from clinicaltrials.gov

Similar Clinical Trials